<DOC>
	<DOCNO>NCT03012386</DOCNO>
	<brief_summary>This proposal test hypothesis chronic treatment sildenafil without use nitric oxide substrate , L-arginine , protect fatty acid induce impairment endothelial function , improve insulin-stimulated microvascular recruitment , insulin sensitivity glucose uptake CD36 rs3211938 G-allele carrier .</brief_summary>
	<brief_title>CD36 Nutrient Delivery Its Dysfunction</brief_title>
	<detailed_description>Subjects carry G-allele CD36 cod SNP rs3211938 result 50 % reduction CD36 level ~25 % African Americans endothelial dysfunction . Endothelial dysfunction result impairment insulin 's vascular action eventually reduce insulin sensitivity . Insulin induce microvascular recruitment via stimulation nitric oxide ( NO ) -cGMP pathway , facilitate nutrient flux , e.g. , glucose skeletal muscle . Elevated fatty acid impair insulin-stimulated microvascular recruitment reduce insulin sensitivity . Chronic treatment sildenafil increase vascularity muscle glucose uptake high fat feed mouse . In human , Drs . Shibao ( PI ) recently report 3-month treatment sildenafil improve insulin sensitivity patient impair glucose tolerance . More relevant project , endothelial dysfunction improve 4-week treatment sildenafil G-allele carrier . This proposal test hypothesis chronic treatment sildenafil without use NO substrate , L-arginine , protect fatty acid induce impairment endothelial function , improve insulin-stimulated microvascular recruitment , insulin sensitivity glucose uptake CD36 rs3211938 G-allele carrier .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Inclusion criterion African American men woman . Age 1850 year BMI 2535 kg/m2 Exclusion criterion : Diabetes type 1 type 2 , define FPG &gt; 126 mg/dL twohour plasma glucose &gt; 200 mg/dL , use antidiabetic medication The use nitrate disease might require use nitrate Pulmonary hypertension Hypertension , define SBP/DBP &gt; 140/90 mm Hg use anti hypertensive agent Use PDE5 inhibitor erectile dysfunction Use alpha blocker Pregnancy breastfeeding . Women childbearing potential require undergone tubal ligation use oral contraceptive barrier method birth control . The use potent CYP3A4 inhibitor . Cardiovascular disease myocardial infarction , presence angina pectoris , significant arrhythmia , congestive heart failure ( left ventricular hypertrophy acceptable ) , deep vein thrombosis , pulmonary embolism , second third degree heart block , mitral valve stenosis , aortic stenosis hypertrophic cardiomyopathy Allergies egg , soy product IntralipidÂ® infusion History serious neurologic disease cerebral hemorrhage , stroke , transient ischemic attack History presence immunological hematological disorder Impaired hepatic function ( aspartate amino transaminase [ AST ] and/or alanine amino transaminase [ ALT ] &gt; 3.0 x upper limit normal range ) Impaired renal failure ( eGFR &lt; 60 mL/min/1.73m2 ) Hematocrit &lt; 34 % Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult Treatment chronic systemic glucocorticoid therapy ( 7 consecutive day 1 month ) History alcohol drug abuse Treatment investigational drug one month precede study Mental condition render subject unable understand nature , scope possible consequence study Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study , investigator discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CD36</keyword>
	<keyword>Endothelial dysfunction</keyword>
	<keyword>African Americans</keyword>
</DOC>